Introduction: Continuous ambulatory peritoneal dialysis (CAPD) treatment is subject to constant changes. Departing from this thesis, it should be analyzed in which respects CAPD treatment at the Heidelberg outpatient clinic has changed when considering demographic data, and CAPD-specific data including infection rates and clinical parameters. Materials and Methods: A retrospective study was carried out in the course of which a cohort of 67 CAPD patients treated before the year 2000 was compared with a cohort of 53 patients treated from the year 2000 on. Demographic data, CAPD-specific and clinical data at the commencement of treatment and data gathered during the observation period thereafter were recorded. Results: The patients of the more recent cohort were 5 years older. At the initiation of treatment, the volume of residual diuresis was higher in the patients treated from 2000 on than in those treated before. The blood pressure in patients belonging to the more recently treated group was also lower than the blood pressure of those treated before. The incidence of peritonitis and exit-site infections has decreased. On the other hand, the hemoglobin level has risen. Discussion: Compared to the past, many parameters have improved. Above all, the findings suggest that medical care and treatment have become better, probably as a result of the modified guidelines. The significant decrease in infections is probably also due to the use of the new dialysis fluids.

Keywords:
Peritoneal dialysis, Peritonitis, Dialysis solutions
1.
Popovich RP, Moncrief JF, Nolph KD, Gjods AJ, Twardowski ZJ, Pyle WK: Continuous ambulatory peritoneal dialysis. Ann Intern Med 1978;88:449–456.
2.
Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al, on behalf of the Euro Balance Trial Group: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408–418.
3.
Simonsen O, Sterner G, Carlsson O, Wieslander A, Rippe B: Improvement of peritoneal ultrafiltration with peritoneal dialysis solution buffered with bicarbonate/lactate mixture. Perit Dial Int 2006;26:353–359.
4.
Nilsson Thorell CB, Muscalu N, Andren AH, Kjellstrand PT, Wieslander AP: Heat sterilization of fluids for peritoneal dialysis gives rise to aldehydes. Perit Dial Int 1993;13:208–213.
5.
Cooker LA, Luneburg P, Faict D, Choo C, Holmes CJ: Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int 1997;17:373–378.
6.
Witowski J, Wisniewska J, Korybalska K, Bender TO, Breborowicz A, Gahl GM, et al: Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001;12:2434–2441.
7.
Do J, Kim Y, Park J, Cho K, Kim T, Yoon K, et al: The effect of low glucose degradation product dialysis solution on epithelial-to-mesenchymal transition in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2005;25:(suppl 3):22–25.
8.
Witowski J, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Jörres A, Lage C, et al, members of the European Balance Trial Group: Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant 2004;19:917–924.
9.
Wieczorowska-Tobis K, Brelinska R, Witowski J, Passlick-Deetjen J, Schaub TP, Schilling H, et al: Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 2004;24:48–57.
10.
Park S, Lee E, Kim I, Kim YJ, Cho D, Kim YL: Effect of glucose degradation products on the peritoneal membrane in a chronic inflammatory infusion model of peritoneal dialysis in the rat. Perit Dial Int 2004;24:115–122.
11.
Witowski J, Jörres A, Korybalska K, Ksiazek K, Wisniewska-Elnur J, Bender TO, Passlick-Deetjen J, Breborowicz A: Glucose degradation products in peritoneal dialysis fluids: do they harm? Kidney Int 2003;63(suppl 84):S148–S151.
12.
Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al: Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298–305.
13.
Rippe B, Simonsen O, Heimbürger O, Christensson A, Haraldsson B, Stelin G, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348–357.
14.
Rippe B, Simonsen O, Wieslander A, Landgren C: Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int 1997;17:27–34.
15.
Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al: Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (balance). Perit Dial Int 2005;25:248–255.
16.
Kasai K, Terawaki H, Tanno Y, Hara Y, Kondo M, Hamaguchi A, et al: Factors influencing residual renal function of CAPD patients. Nippon Jinzo Gakkai Shi 1999;41:726–730.
17.
Frankenfield DL, Prowant BF, Flanigan MJ, Frederick PR, Bailie GR, Helgerson SD, et al: Trends in clinical indicators of care for adult peritoneal dialysis patients in the United States from 1995 to 1997. ESRD Core Indicators Workgroup. Kidney Int 1999;55:1998–2010.
18.
Ermolenko VM, Melikian AM, Ivashchenko MA, Shutov EV, Zenchenko IV: Continuous ambulatory peritoneal dialysis in patients with diabetes mellitus. Ter Arkh 2000;72:55–57.
19.
Stein G, Funfstuck R, Schiel R: Diabetes mellitus and dialysis. Minerva Urol Nefrol 2004;56:289–303.
20.
Marshall J, Jennings P, Scott A, Fluck RJ, McIntyre CW: Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003;64:1480–1486.
21.
The current state of chronic dialysis treatment in Japan (as of December 31, 2000). Ther Apher Dial 2003;7:3–35.
22.
Krishnan M, Lok CE, Jassal SV: Epidemiology and demographic aspects of treated end-stage renal disease in the elderly. Semin Dial 2002;15:79–83.
23.
Mc Donald SP, Russ GR, Kerr PG, Collins JF: ESRD in Australia and New Zealand at the end of the millennium: a report from the ANZDATA registry. Am J Kidney Dis 2002;40:1122–1131.
24.
Verwiebe R, Knauf H: Renale Erkrankungen im Alter aus internistischer Sicht. Diagnostik und Therapie. Fortschr Med 1995;113:418–422.
25.
Jager KJ, van Dijk PC, Dekker FW, Stengel B, Simpson K, Briggs JD: The epidemic of aging in renal replacement therapy: an update on elderly patients and their outcomes. Clin Nephrol 2003;60:352–360.
26.
Termorshuizen F, Korevaar JC, Dekker FW, Jager KJ, van Manen JG, Boeschoten EW, et al: Time trends in initiation and dose of dialysis in end-stage renal disease patients in The Netherlands. Nephrol Dial Transplant 2003;18:552–558.
27.
Feest TG, Rajamahesh J, Byrne C, Ahmad A, Ansell D, Burden R, et al: Trends in adult renal replacement therapy in the UK: 1982–2002. QJM 2005;98:21–28.
28.
Baek MY, Kwon TH, Kim YL, Cho DK: CAPD, an acceptable form of therapy in elderly ESRD patients: a comparative study. Adv Perit Dial 1997;13:158–161.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.